Primary biliary cirrhosis and bile acids

Clinics and Research in Hepatology and Gastroenterology

Volumn 36, Issue SUPPL.1, 2012, Pages

  Corpechot, Christophe ^a  

^a HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BEZAFIBRATE; BILE ACID; BUDESONIDE; FARNESOID X RECEPTOR; FENOFIBRATE; G PROTEIN COUPLED RECEPTOR; HORMONE RECEPTOR STIMULATING AGENT; LIVER ENZYME; OBETICHOLIC ACID; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR ALPHA AGONIST; URSODEOXYCHOLIC ACID;

ABDOMINAL PAIN; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CLINICAL PRACTICE; DIARRHEA; FLATULENCE; HOMEOSTASIS; HUMAN; HYDROPHILICITY; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER TRANSPLANTATION; META ANALYSIS (TOPIC); NONHUMAN; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PRIMARY BILIARY CIRRHOSIS; PRURITUS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; TREATMENT RESPONSE; WEIGHT GAIN;

ANTI-INFLAMMATORY AGENTS; BILE ACIDS AND SALTS; CHOLAGOGUES AND CHOLERETICS; HUMANS; IMMUNOLOGIC FACTORS; LIVER CIRRHOSIS, BILIARY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; TREATMENT OUTCOME; URSODEOXYCHOLIC ACID;

EID: 84868689299     PISSN: 22107401     EISSN: 2210741X     Source Type: Journal    
DOI: 10.1016/S2210-7401(12)70016-5     Document Type: Article

References (80)

1. Poupon R., Chrétien Y., Poupon R.E., Ballet F., Calmus Y., Darnis F. Is ursodeoxycholic acid an effective treatment for primary biliary cirrhosis?. Lancet 1987, 1:834-836.
2. Leuschner U., Fischer H., Kurtz W., Güldütuna S., Hübner K., Hellstern A., et al. Ursodeoxycholic acid in primary biliary cirrhosis: results of a controlled double-blind trial. Gastroenterology 1989, 97:1268-1274.
3. Poupon R.E., Chrétien Y., Poupon R., Paumgartner G. Serum bile acids in primary biliary cirrhosis: effect of ursodeoxycholic acid therapy. Hepatology 1993, 17:599-604.
4. Lindor K.D., Lacerda M.A., Jorgensen R.A., DeSotel C.K., Batta A.K., Salen G., et al. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis. Am J Gastroenterol 1998, 93:1498-1504.
5. Marteau P., Chazouilléres O., Myara A., Jian R., Rambaud J.C., Poupon R., et al. Effect of chronic administration of ursodeoxycholic acid on the ileal absorption of endogenous bile acids in man. Hepatology 1990, 12:1206-1208.
6. Eusufzai S., Ericsson S., Cederlund T., Einarsson K., Angelin B. Effect of ursodeoxycholic acid treatment on ileal absorption of bile acids in man as determined by the SeHCAT test. Gut 1991, 32:1044-1048.
7. Paumgartne r G., Beuers U. Ursodeoxycholic acid in cholestatic liver disease: mechanisms of action and therapeutic use revisited. Hepatology 2002, 36:525-531.
8. Marschall H.U., Wagner M., Zollner G., Fickert P., Diczfalusy U., Gumhold J., et al. Complementary stimulation of hepatobiliary transport and detoxification systems by rifampicin and ursodeoxycholic acid in humans. Gastroenterology 2005, 129:476-485.
9. Prieto J., García N., Martí-Climent J.M., Peñuelas I., Richter J.A., Medina J.F. Assessment of biliary bicarbonate secretion in humans by positron emission tomography. Gastroenterology 1999, 117:167-172.
10. Rodrigues C.M., Fan G., Ma X., Kren B.T., Steer C.J. A novel role for ursodeoxycholic acid in inhibiting apoptosis by modulating mitochondrial membrane perturbation. J Clin Invest 1998, 101:2790-2799.
11. Ikegami T., Matsuzaki Y., Fukushima S., Shoda J., Olivier J.L., ouscarel B., et al. Suppressive effect of ursodeoxycholic acid on type IIA phospholipase A2 expression in HepG2 cells. Hepatology 2005, 41:896-905.
12. Calmus Y., Gane P., Rouger P., Poupon R. Hepatic expression of class I and class II major histocompatibility complex molecules in primary biliary cirrhosis: effect of ursodeoxycholic acid. Hepatology 1990, 11:12-15.
13. Poupon R. Ursodeoxycholic acid and bile acids mimetics as therapeutic agents for cholestatic liver diseases: an overview of their mechanisms of action. Clin Res Hepatol Gastroenterol 2012;in press.
14. Gong Y., Huang Z., Christensen E., Gluud C. Ursodeoxycholic acid for patients with primary biliary cirrhosis: an updated systematic review and meta-analysis of randomized clinical trials using Bayesian approach as sensitivity analyses. Am J Gastroenterol 2007, 102:1799-1807.
15. Poupon R.E., Balkau B., Eschwège E., Poupon R. A multicenter, controlled trial of ursodiol for the treatment of primary biliary cirrhosis. N Engl J Med 1991, 324:1548-1554.
16. Heathcote E.J., Cauch-Dudek K., Walker V., Bailey R.J., Blendis L.M., Ghent C.N., et al. The Canadian Multicenter Double-blind Randomized Controlled Trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1994, 19:1149-1156.
17. Lindor K., Therneau T. Survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Gastroenterology 1996, 111:1782-1783.
18. Poupon R.E., Lindor K.D., Cauch-Dudek K., Dickson E.R., Poupon R., Heathcote E.J. Combined analysis of randomized controlled trials of ursodeoxycholic acid in primary biliary cirrhosis. Gastroenterology 1997, 113:884-890.
19. Goulis J., Leandro G., Burroughs A.K. Randomised controlled trials of ursodeoxycholic-acid therapy for primary biliary cirrhosis: a meta-analysis. Lancet 1999, 354:1053-1060.
20. Van Hoogst raten H.J., De Smet M.B., Renooij W., Breed J.G., Engels L.G., Den Ouden-Muller J.W., et al. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10mg/kg or 20mg/kg. Dutch Multicentre PBC Study Group. Aliment Pharmacol Ther 1998, 12:965-971.
21. Angulo P., Dickson E.R., Therneau T.M., Jorgensen R.A., Smith C., DeSotel C.K., et al. Comparison of three doses of ursodeoxycholic acid in the treatment of primary biliary cirrhosis: a randomized trial. J Hepatol 1999, 30:830-835.
22. Corpechot C., Carrat F., Bonnand A.M., Poupon R.E., Poupon R. The effect of ursodeoxycholic acid therapy on liver fibrosis progression in primary biliary cirrhosis. Hepatology 2000, 32:1196-1199.
23. Poupon R.E., Lindor K.D., Parés A., Chazouillères O., Poupon R., Heathcote E.J. Combined analysis of the effect of treatment with ursodeoxycholic acid on histologic progression in primary biliary cirrhosis. J Hepatol 2003, 39:12-16.
24. Lindor K.D., Dickson E.R., Baldus W.P., Jorgensen R.A., Ludwig J., Murtaugh P.A., et al. Ursodeoxycholic acid in the treatment of primary biliary cirrhosis. Gastroenterology 1994, 106:1284-1290.
25. Combes B., Carithers R.L., Maddrey W.C., Lin D., McDonald M.F., Wheeler D.E., et al. A randomized, double-blind, placebocontrolled trial of ursodeoxycholic acid in primary biliary cirrhosis. Hepatology 1995, 22:759-766.
26. Poupon R.E., Bonnand A.M., Chretien Y., Poupon R. Ten-year survival in ursodeoxycholic acid-treated patients with primary biliary cirrhosis. Hepatology 1999, 29:1668-1671.
27. Koulentaki M., Moscandrea J., Dimoulios P., Chatzicostas C., Kouroumalis E.A. Survival of anti-mitochondrial antibody- positive and -negative primary biliary cirrhosis patients on ursodeoxycholic acid treatment. Dig Dis Sci 2004, 49:1190-1195.
28. ter Borg P.C., Schalm S.W., Hansen B.E., van Buuren H.R. Prognosis of ursodeoxycholic Acid-treated patients with primary biliary cirrhosis. Results of a 10-yr cohort study involving 297 patients. Am J Gastroenterol 2006, 101:2044-2050. Dutch PBC Study Group.
29. Pares A., Caballeria L., Rodes J. Excellent long-term survival in patients with primary biliary cirrhosis and biochemical response to ursodeoxycholic Acid. Gastroenterology 2006, 130:715-720.
30. Leuschner M. UDCA, PBC, and biochemistry, what does normal mean?. Gut 2000, 47:595-596.
31. Angulo P., Batts K.P., Therneau T.M., Jorgensen R.A., Dickson E.R., Lindor K.D. Long-term ursodeoxycholic acid delays histological progression in primary biliary cirrhosis. Hepatology 1999, 29:644-647.
32. Locke G.R., Therneau T.M., Ludwig J., Dickson E.R., Lindor K.D. Time course of histological progression in primary biliary cirrhosis. Hepatology 1996, 23:52-56.
33. Corpechot C., Carrat F., Poupon R., Poupon R.E. Primary biliary cirrhosis: incidence and predictive factors of cirrhosis development in ursodiol-treated patients. Gastroenterology 2002, 122:652-658.
34. Jackson H., Solaymani-Dodaran M., Card T.R., Aithal G.P., Logan R., West J. Influence of ursodeoxycholic acid on the mortality and malignancy associated with primary biliary cirrhosis: a population-based cohort study. Hepatology 2007, 46:1131-1137.
35. Kuiper E.M., Hansen B.E., Adang R.P., van Nieuwkerk C.M., Timmer R., Drenth J.P., et al. Relatively high risk for hepatocellular carcinoma in patients with primary biliary cirrhosis not responding ursodeoxycholic acid. Eur J Gastroenterol Hepatol 2010, 22:1495-1502.
36. Liermann Garcia R.F., Evangelista Garcia C., McMaster P., Neuberger J. Transplantation for primary biliary cirrhosis: retrospective analysis of 400 patients in a single center. Hepatology 2001, 33:22-27.
37. Lee J., Bel anger A., Doucette J.T., Stanca C., Friedman S., Bach N. Transplantation trends in primary biliary cirrhosis. Clin Gastroenterol Hepatol 2007, 5:1313-1315.
38. Corpechot C., Poupon R. Geotherapeutics of primary biliary cirrhosis: bright and sunny around the Mediterranean but still cloudy and foggy in the United Kingdom. Hepatology 2007, 46:963-965.
39. Kuiper E.M., Hansen B.E., Metselaar H.J., de Man R.A., Haagsma E.B., van Hoek B., et al. Trends in liver transplantation for primary biliary cirrhosis in the Netherlands 1988-2008. BMC Gastroenterol 2010, 10:144.
40. Corpechot C., Carrat F., Bahr A., Chrétien Y., Poupon R.E., Poupon R. The effect of ursodeoxycholic acid therapy on the natural course of primary biliary cirrhosis. Gastroenterology 2005, 128:297-303.
41. Shapiro J.M., Smith H., Schaffner F. Serum bilirubin: a prognostic factor in primary biliary cirrhosis. Gut 1979, 20:137-140.
42. Angulo P., Lindor K.D., Therneau T.M., Jorgensen R.A., Malinchoc M., Kamath P.S., et al. Utilization of the Mayo risk score in patients with primary biliary cirrhosis receiving ursodeoxycholic acid. Liver 1999, 19:115-121.
43. Corpechot C., Abenavoli L., Rabahi N., Chrétien Y., Andréani T., Johanet C., et al. Biochemical response to ursodeoxycholic acid and long-term prognosis in primary biliary cirrhosis. Hepatology 2008, 48:871-877.
44. Kuiper E.M., Hansen B.E., de Vries R.A., den Ouden-Muller J.W., van Ditzhuijsen T.J., Haagsma E.B., et al. Improved prognosis of patients with primary biliary cirrhosis that have a biochemical response to ursodeoxycholic acid. Gastroenterology 2009, 136:1281-1287.
45. Kumagi T., Guindi M., Fischer S.E., Arenovich T., Abdalian R., Coltescu C., et al. Baseline ductopenia and treatment response predict long-term histological progression in primary biliary cirrhosis. Am J Gastroenterol 2010, 105:2186-2194.
46. Azemoto N., Kumagi T., Abe M., Konishi I., Matsuura B., Hiasa Y., et al. Biochemical response to ursodeoxycholic acid predicts long-term outcome in Japanese patients with primary biliary cirrhosis. Hepatol Res 2011, 41:310-317.
47. Meaney C., Kumagi T., Al-Harthy N., Acarsu U., Coltescu C., Hirschfield G.M., et al. The toronto western hospital PBC study: the AST to platelet ratio index (APRI) is an effective predictor of long-term outcome in patients with primary biliary cirrhosis (Abstract). Hepatology 2010, 52(Suppl 1):491A.
48. Silveira M.G., Brunt E.M., Heathcote J., Gores G.J., Lindor K.D., Mayo M.J. American Association for the Study of Liver Diseases endpoints conference: design and endpoints for clinical trials in primary biliary cirrhosis. Hepatology 2010, 52:349-359.
49. Corpechot C., Carrat F., Poujol-Robert A., Gaouar F., Wendum D., Chazouillères O., et al. Noninvasive elastography-based assessment of liver fibrosis progression and prognosis in primary biliary cirrhosis. Hepatology 2012, 56:198-208.
50. Roda E., Azzaroli F., Nigro G., Piazza F., Jaboli F., Ferrara F., et al. Improved liver tests and greater biliary enrichment with high dose ursodeoxycholic acid in early stage primary biliary cirrhosis. Dig Liver Dis 2002, 34:523-527.
51. Dilger K., Hohenester S., Winkler-Budenhofer U., Bastiaansen B.A., Schaap F.G., Rust C., et al. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health. J Hepatol 2012, 57:133-140.
52. Roda E., Buonfiglioli F., Lisotti A., Simoni P., Roda A., Mazella G. Treatment of early (I-II stage) primary biliary cirrhosis (PBC): high versus standard UDCA doses after 15 years follow-up. A randomized open controlled trial (Abstract). Heaptology 2011, 54(Suppl 1):1209A.
53. Chazouillè res O., Wendum D., Serfaty L., Montembault S., Rosmorduc O., Poupon R. Primary biliary cirrhosis-autoimmune hepatitis overlap syndrome: clinical features and response to therapy. Hepatology 1998, 28:296-301.
54. Leuschner M., Maier K.P., Schlichting J., Strahl S., Herrmann G., Dahm H.H., et al. Oral budesonide and ursodeoxycholic acid for treatment of primary biliary cirrhosis: results of a prospective double-blind trial. Gastroenterology 1999, 117:918-925.
55. Rautiainen H., Kärkkäinen P., Karvonen A.L., Nurmi H., Pikkarainen P., Nuutinen H., et al. Budesonide combined with UDCA to improve liver histology in primary biliary cirrhosis: A three-year randomized trial. Hepatology 2005, 41:747-752.
56. Rabahi N., Chrétien Y., Gaouar F., Wendum D., Serfaty L., Chazouillères O., et al. Triple therapy with ursodeoxycholic acid, budesonide and mycophenolate mofetil in patients with features of severe primary biliary cirrhosis not responding to ursodeoxycholic acid alone. Gastroenterol Clin Biol 2010, 34:283-287.
57. Iwasaki S., Ohira H., Nishiguchi S., Zeniya M., Kaneko S., Onji M., et al. The efficacy of ursodeoxycholic acid and bezafibrate combination therapy for primary biliary cirrhosis: A prospective, multicenter study. Hepatol Res 2008, 38:557-564.
58. Levy C., Peter J.A., Nelson D.R., Keach J., Petz J., Cabrera R., et al. Pilot study: fenofibrate for patients with primary biliary cirrhosis and an incomplete response to ursodeoxycholic acid. Aliment Pharmacol Ther 2011, 33:235-242.
59. Honda A, I kegami T, Nakamuta M, Miyazaki T, Iwamoto J, Hirayama T, et al. Anticholestatic effects of bezafibrate in patients with primary biliary cirrhosis treated with ursodeoxycholic acid. Hepatology 2012;in press.
60. Mason A.L., Luketic V.A., Lindor K.D., Hirschfield G.M., Gordon S.C., Mayo M.J., et al. Farnesoid - X Receptor Agonists: a New Class of Drugs for the Treatment of PBC? An International Study Evaluating the Addition of Obeticholic Acid (INT-747) to Ursodeoxycholic Acid (Abstract). Hepatology 2010, 52(Suppl 1):357A.
61. Fickert P., Wagner M., Marschall H.U., Fuchsbichler A., Zollner G., Tsybrovskyy O., et al. 24-norUrsodeoxycholic acid is superior to ursodeoxycholic acid in the treatment of sclerosing cholangitis in Mdr2 (Abcb4) knockout mice. Gastroenterology 2006, 130:465-481.
62. Lindor K.D., Gershwin M.E., Poupon R., Kaplan M., Bergasa N.V., Heathcote E.J., et al. Primary biliary cirrhosis. Hepatology 2009, 50:291-308.
63. EASL Clinical Practice Guidelines: management of cholestatic liver diseases. J Hepatol 2009, 51:237-267. European As sociation for the Study of the Liver.
64. Hempfling W., Dilger K., Beuers U. Systematic review: ursodeoxycholic acid--adverse effects and drug interactions. Aliment Pharmacol Ther 2003, 18:963-972.
65. Siegel J.L., Jorgensen R., Angulo P., Lindor K.D. Treatment with ursodeoxycholic acid is associated with weight gain in patients with primary biliary cirrhosis. J Clin Gastroenterol 2003, 37:183-185.
66. Kuiper E.M., Hansen B.E., Lesterhuis W., Robijn R.J., Thijs J.C., Engels L.G., et al. The long-term effect of ursodeoxycholic acid on laboratory liver parameters in biochemically non-advanced primary biliary cirrhosis. Clin Res Hepatol Gastroenterol 2011, 35:29-33.
67. Jorgensen R.A., Dickson E.R., Hofmann A.F., Rossi S.S., Lindor K.D., et al. Characterisation of patients with a complete biochemical response to ursodeoxycholic acid. Gut 1995, 36:935-938.
68. Poupon R., Chrétien Y., Chazouillères O., Poupon R.E. Pregnancy in women with ursodeoxycholic acid-treated primary biliary cirrhosis. J Hepatol 2005, 42:418-419.
69. Westbrook R., Hughes S.A., O'Grady J.G., Devlin J., Harrison P.M., Heneghan M.A. Pregnancy in cholestatic disease (Abstract). Hepatology 2011, 54(Suppl 1):926A.
70. Kumagi T., Al-Harthy N., Coltescu C., Hirschfield G.M. Pregnancy and primary biliary cirrhosis: cross-sectional and retrospective analyses demonstrate a high prevalence of symptoms and a risk of disease progression. Hepatology 2009, 50(Suppl 4):1008A.
71. Pellicciari R., Fiorucci S., Camaioni E., Clerici C., Costantino G., Maloney P.R., et al. 6alpha-ethyl-chenodeoxycholic acid (6-ECDCA), a potent and selective FXR agonist endowed with anticholestatic activity. J Med Chem 2002, 45:3569-3572.
72. Song K.H., Li T., Owsley E., Strom S., Chiang J.Y. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7alpha-hydroxylase gene expression. Hepatology 2009, 49:297-305.
73. Hofmann A.F., Mangelsdorf D.J., Kliewer S.A. Chronic diarrhea due to excessive bile acid synthesis and not defective ileal transport: a new syndrome of defective fibroblast growth factor 19 release. Clin Gastroenterol Hepatol 2009, 7:1151-1154.
74. Fiorucci S., Antonelli E., Rizzo G., Renga B., Mencarelli A., Riccardi L., et al. The nuclear receptor SHP mediates inhibition of hepatic stellate cells by FXR and protects against liver fibrosis. Gastroenterology 2004, 127:1497-1512.
75. Fiorucci S., Rizzo G., Antonelli E., Renga B., Mencarelli A., Riccardi L., et al. Cross-talk between farnesoid-X-receptor (FXR) and peroxisome proliferator-activated receptor gamma contributes to the antifibrotic activity of FXR ligands in rodent models of liver cirrhosis. J Pharmacol Exp Ther 2005, 315:58-68.
76. Kowdley K.V., Jones D., Luketic V., Chapman R., Burroughs A., Hirschfield G., et al. An international study evaluating the farnesoid X receptor agonist obeticholic acid as monotherapy in PBC (Abstract). J Hepatol 2011, 54(Suppl 1):S13.
77. Marschall H.U., Luketic V., Lövgren-Sandblom A., Benthin L., Kowdley K., Hirschfield G., et al. The farnesoid X receptor (FXR) agonist obeticholic acid (OCA) increases plasma FGF-19 concentrations and decreases bile acid synthesis in primary biliary cirrhosis (PBC) (Abstract). J Hepatol 2012, 56(Suppl 2):S377.
78. Sato H., Macchiarulo A., Thomas C., Gioiello A., Une M., Hofmann A.F., et al. Novel potent and selective bile acid derivatives as TGR5 agonists: biological screening, structure-activity relationships, and molecular modeling studies. J Med Chem 2008, 51:1831-1841.
79. Baghdasaryan A., Claudel T., Gumhold J., Silbert D., Adorini L., Roda A., et al. Dual farnesoid X receptor/TGR5 agonist INT-767 reduces liver injury in the Mdr2-/-(Abcb4-/-) mouse cholangiopathy model by promoting biliary HCO output. Hepatology 2011, 54:1303-1312.
80. Corpechot C., Chazouillères O., Poupon R. Early primary biliary cirrhosis: biochemical response to treatment and prediction of long-term outcome. J Hepatol 2011, 55:1361-1367.